We use cookies to further personalise and enhance the user experience, conduct analytical research (for example, counting visits and traffic sources), place advertisements and contact third parties. Users can manage their cookie settings by clicking the "Choose your preferences" link.

Cookie policy
Published 2022-01-21

Schibsted invests in the Norwegian healthtech company Maja

Maja, a company offering a digital network of licensed doctors to women, has rapidly established itself as one of the largest digital clinics on the Norwegian market.

Harald Dobloug, founder and CEO of Maja.

Schibsted Ventures now joins the company and investment manager Kajsa Gatenbeck becomes a member of the board.

Maja was launched in 2020 and already today provides advice and treatments to thousands of young women every month. “Many young women in Norway find it uncomfortable to visit a clinic to get contraceptives. With Maja, we lower that threshold through a simple, digital service for guidance and treatment,” says Harald Dobloug, founder and CEO of Maja.

Schibsted Ventures is now investing 16 million (NOK) in a new issue of a total of 30 million, after Maja’s services has proven to be a very attractive offer.

Investment manager Kajsa Gatenbeck becomes a member of the Maja board.

“We are continuing our focus on digital health services, and it is amazing that so much is currently happening within female health in the Nordic region. Maja is a great example of a company that successfully built a digital service with the patient in focus while minimising the stigma around problems that many women unfortunately experience. We are very happy to contribute further to that development,” says Kajsa Gatenbeck, investment manager at Schibsted.

“I am so proud of what we have achieved so far, and with Schibsted’s investment, we get the opportunity both to develop the service and expand. We are currently looking at several markets, including Sweden. Despite the fact that both Norway and Sweden offer similar, state-subsidised care, we see that the willingness to pay is very high in this health area. Our view is that we can cover the needs where existing models aren’t good enough,” says Harald Dobloug.